18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer

Journal of Nuclear Medicine

Volumn 50, Issue 11, 2009, Pages 1770-1776

  Kaira, Kyoichi ^a   Oriuchi, Noboru ^a   Shimizu, Kimihiro ^a   Tominaga, Hideyuki ^a   Yanagitani, Noriko ^a   Sunaga, Noriaki ^a   Ishizuka, Tamotsu ^a   Kanai, Yoshikatsu ^b   Mori, Masatomo ^a   Endo, Keigo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

18F methyltyrosine; 18F fluorodeoxyglucose; Lung cancer; Positron emission tomography; Prognostic factor

Indexed keywords

ALPHA METHYL TYROSINE F 18; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; TEGAFUR; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FLUORINE; METIROSINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; KAPLAN MEIER METHOD; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; UNIVARIATE ANALYSIS; ADENOCARCINOMA; ANALYSIS OF VARIANCE; CHEMISTRY; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALPHA-METHYLTYROSINE; ANALYSIS OF VARIANCE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SURVIVAL RATE;

EID: 70350712300     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.066837     Document Type: Article

References (31)

1. Ettinger DS. Overview and state of the art in the management of lung cancer. Oncology. 2004;18(suppl 4):3-9.
2. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of prognosis. Chest. 2002;122:1037-1057.
3. Clinical Practice Guidelines for the Treatment of Unresectable Non-Small Cell Lung Cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol. 1997;15:2996-3018.
4. Mcloud TC, Bourgouin PM, Greenberg RW, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology. 1992;182:319-323.
5. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236:1011-1019.
6. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254-261. (Pubitemid 30490393)
7. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507. (Pubitemid 36706537)
8. Sasaki R, Komaki R, Macapinlac H, et al. [18F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23:1136-1143. (Pubitemid 46202269)
9. 18F-fluoro-2-deoxy-glucose- positron emission tomography in non-small cell lung cancer: an analysis of 125 cases. J Clin Oncol. 1999;17:3201-3206.
10. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE II, Patz EF Jr. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol. 2008;26:1459-1464.
11. Vesselle H, Freeman JD, Wiens L, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res. 2007;13:3255-3263. (Pubitemid 46944910)
12. Tomiyoshi K, Amed K, Muhammad S, et al. Synthesis of new fluorine-18 labeled amino acid radiopharmaceutical: L-F-alpha-methyl tyrosine using separation and purification system. Nucl Med Commun. 1997;18:169-175.
13. Inoue T, Shibasaki T, Oriuchi N, et al. 18F α-methyl tyrosine PET studies in patients with brain tumors. J Nucl Med. 1999;40:399-405. (Pubitemid 29120112)
14. Watanabe H, Inoue T, Shinozaki T, et al. PET imaging of musculoskeletal tumors with fluorine-18 α-methyl tyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med. 2000;27:1509-1517. (Pubitemid 30780246)
15. Inoue T, Koyama K, Oriuchi N, et al. Detection of malignant tumors: wholebody PET with fluorine-18-α-methyl tyrosine versus FDG-preliminary study. Radiology. 2001;220:54-62. (Pubitemid 32577959)
16. 18F-fluorodeoxyglucose in sarcoidosis patients. Chest. 2007;131:1019-1027.
17. Kaira K, Oriuchi N, Otani Y, et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res. 2007;13:6369-6378. (Pubitemid 350075026)
18. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718-1723. (Pubitemid 27260108)
19. Oriuchi N, Tomiyoshi K, Inoue T, et al. Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma. J Nucl Med. 1996;37:457-462. (Pubitemid 26094272)
20. Inoue T, Oriuchi N, Kunio M, et al. Accuracy of standardized uptake value (SUV) measured by simultaneous emission and transmission scanning in PET oncology. Nucl Med Commun. 1999;20:849-857. (Pubitemid 29508709)
21. Uchino H, Kanai Y, Kim DK, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002;61:729-737. (Pubitemid 34273151)
22. Kim DK, Kanai Y, Choi HW, et al. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta. 2002;1565:112-122. (Pubitemid 35239839)
23. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998;273:23629-23632. (Pubitemid 28435687)
24. Yanagida O, Kanai Y, Chairoungdua A, et al. Human L-type amino acid transporter 1 (LAT 1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514:291-302. (Pubitemid 32831016)
25. Nawashiro H, Otani N, Shinomiya N, et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer. 2006;119:484-492. (Pubitemid 43955699)
26. Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer. 2008;98:742-748. (Pubitemid 351272621)
27. Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer. 2009;66:120-126.
28. 11C-methionine for the detection of hilar and mediastinal lymph node metastasis in lung cancer. J Nucl Med. 2000;41:283-290.
29. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer. 2004;45:19-27. (Pubitemid 38757828)
30. Sagawa M, Higashi K, Sugita M, et al. Fluorodeoxyglucose uptake correlates with the growth pattern of small peripheral pulmonary adenocarcinoma. Surg Today. 2006;36:230-234. (Pubitemid 43288715)
31. Oriuchi N, Higuchi T, Ishikita T, et al. Present role and future prospect of positron emission tomography in clinical oncology. Cancer Sci. 2006;97:1291-1297. (Pubitemid 44614979)